reports
UNITED LABS.INTL.HDG. increases its risk exposure and slightly lowers ...
UNITED LABS.INTL.HDG. (HK), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 2 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date March 15, 2022, the closing price was HKD ...
United Laboratories International Holdings Ltd: 1 director sold
A director at United Laboratories International Holdings Ltd sold 50,000 shares at 7.200HKD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Health Care Hitting On All Cylinders Global equities remain in a short-term consolidation phase, however we continue to believe the longer-term trend is up and to the right for the MSCI ACWI following the late-October breakout... see chart below. • Market Ignoring Negative Headlines. Global equity markets continue to generally shrug off seemingly bearish headlines surrounding trade, Trump impeachment hearings, and ongoing protests in Hong Kong. This tells us that the good outweighs the bad i...
FME FRESENIUS MEDICAL CARE AG
UNJ UNITED LABORATORIES INTERNATIONAL HOLDINGS LTD.
300482 GUANGZHOU WONDFO BIOTECH CO. LTD. CLASS A
AFX CARL ZEISS MEDITEC AG
EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
FRE FRESENIUS SE & CO. KGAA
BAYN BAYER AG
GEN GENMAB A/S
600763 TOPCHOICE MEDICAL CORP. CLASS A
COH COCHLEAR LIMITED
600276 JIANGSU HENGRUI MEDICINE CO. LTD. CLASS A
4530 HISAMITSU PHARMACEUTICAL CO. INC.
4521 KAKEN PHARMACEUTICAL CO. LTD.
002007 HUALAN BIOLOGICAL ENGINEERING INC. CLASS A
FLRY3 FLEURY SA
7780 MENICON
4544 H.U.GROUP HOLDINGS INC.
4547 KISSEI PHARMACEUTICAL CO. LTD.
7447 NAGAILEBEN CO. LTD.
4516 NIPPON SHINYAKU CO. LTD.
8086 NIPRO CORPORATION
SHL SONIC HEALTHCARE LIMITED
4543 TERUMO CORPORATION
000513 LIVZON PHARMACEUTICAL GROUP INC. CLASS A
YPSN YPSOMED HOLDING AG
109J ASPEN PHARMACARE HOLDINGS LIMITED
ORNBV ORION OYJ CLASS B
DIA DIASORIN S.P.A.
300142 WALVAX BIOTECHNOLOGY CO. LTD. CLASS A
MDC MEDICLINIC INTERNATIONAL PLC
VIFN VIFOR PHARMA AG
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.